The success of a TNFalpha blocker therapy e. g. in
patients with inflammatory bowel diseases is dependent on the choice of the
appropriate drug, an effective dosage and, when indicated, the administration of
immunosuppressive medication. For an optimal individual control of these
parameters, Immundiagnostik now offers the following contract analyses of
TNFalpha blocker drug levels:
IDKmonitor®
-determination of TNFalpha blocker drug levels
- Specific ELISA analysis of TNFalpha blocker: drug level of Infliximab (e.g.
Remicade®), drug level of Adalimumab (e.g. Humira®) or drug level of Golimumab
(e. g. Simponi®)
- Drug level determination in serum and EDTA plasma
- High analytic sensitivity
- Regular monitoring of trough levels facilitates dosage adjustments and
provides information about therapy failure
